An Open label, Multi-Center, Phase I/II study of vemurafenib in patients with unresectable or Metastatic Melanoma with BRAFV600 Mutation

Trial Profile

An Open label, Multi-Center, Phase I/II study of vemurafenib in patients with unresectable or Metastatic Melanoma with BRAFV600 Mutation

Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 May 2016

At a glance

  • Drugs Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 11 Dec 2014 New source identified and integrated (Japan Pharmaceutical Information Center: JAPIC Clinical Trials Information - JapicCTI-121940).
    • 17 Aug 2011 Planned initiation date changed from 1 Jun 2011 to 1 Jun 2012.
    • 16 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top